Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results

Ranjana H. Advani, Alison J. Moskowitz, Nancy L. Bartlett, Julie M. Vose, Radhakrishnan Ramchandren, Tatyana A. Feldman, Ann S. LaCasce, Beth A. Christian, Stephen M. Ansell, Craig H. Moskowitz, Lisa Brown, Chiyu Zhang, David Taft, Sahar Ansari, Mariana Sacchi, Linda Ho, Alex F. Herrera

Blood (2021) 138 (6): 427–438.

https://doi.org/10.1182/blood.2020009178

Published: 2021

Includes: Supplemental data

Journal Articles

A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma

Walter Hanel, MD, Beth A. Christian, MD, Kami J. Maddocks, MD, Narendranath Epperla, MDMS, Basem M. William, MDMRCP, Samantha Jaglowski, MD MPH, David A. Bond, MD, Yazeed Sawalha, MD, John C. Reneau, MDPhD, Jonathan E Brammer, MD, Robert Baiocchi, MD PhD, Kristie A. Blum, MD, Lapo Alinari, MD PhD

Blood (2020) 136 (Supplement 1): 29.

https://doi.org/10.1182/blood-2020-141243

Published: 2020

Journal Articles

Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study

Pier Luigi Zinzani, MD, Vladimir Melnichenko, Krimo Bouabdallah, MD, Jan Walewski, MD PhD, Alejandro Majlis, MD, Laura Fogliatto, MDPhD, Dolores Caballero, MD PhD, Beth A. Christian, MD, Zafer Gulbas, MD, Muhit Özcan, MD, Gilles Salles, MD PhD, Margaret A. Shipp, MD, Seth Thompson, Robert J Orlowski, MD, Patricia Marinello, Philippe Armand, MD PhD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-137080

Published: 2020

Journal Articles

Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-135870

Published: 2020

Journal Articles

A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results

Francisco J. Hernandez-Ilizaliturri, MD, Ian W. Flinn, MD PhD, John Kuruvilla, MD, Sarit E Assouline, MD MSc, Matthew L. Ulrickson, MD, Beth A. Christian, MD, Daniel J. Landsburg, MD, Monic Stuart, MD MPH, Henry Lowman, PhD, Nancy Levin, PhD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-142859

Published: 2020

Journal Articles

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Basem M. William, MRCP,MD, Ying Huang, MS, MA, Amy Johnson, MD, Jonathan E Brammer, MD, John C. Reneau, MD PhD, Joseph Maakaron, MD, Ruth Larbi, Cara Grantier, CNP, MPH, MS, Corinne Hoffman, MS, CNP, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Narendranath Epperla, MDMS, Beth A. Christian, MD, Lapo Alinari, MD PhD, Kami J. Maddocks, MD, Catherine Chung, MD

Blood (2019) 134 (Supplement_1): 2853.

https://doi.org/10.1182/blood-2019-123801

Published: 2019

Journal Articles

Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study

Alison J. Moskowitz, MD, Ranjana H Advani, MD, Nancy L. Bartlett, MD, Julie M Vose, MDMBA, Radhakrishnan Ramchandren, MD, Tatyana A. Feldman, MD, Ann S. LaCasce, MD MMSc, Beth A. Christian, MD, Stephen M Ansell, MD PhD, Craig H. Moskowitz, Lisa Brown, David Taft, Sahar Ansari, Daniel E. Zak, PhD, Mariana Sacchi, MD, Thomas Manley, MD, Alex F. Herrera, MD

Blood (2019) 134 (Supplement_1): 238.

https://doi.org/10.1182/blood-2019-122576

Published: 2019

Journal Articles

Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Beth A. Christian, MD, Ying Huang, MS, MA, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Jonathan E Brammer, MD, Narendranath Epperla, MDMS, Samantha Jaglowski, MDMPH, Basem M. William, MRCP,MD, Farrukh T. Awan, MD, Kami J. Maddocks, MD, Kristie A. Blum, MD

Blood (2019) 134 (Supplement_1): 4082.

https://doi.org/10.1182/blood-2019-126242

Published: 2019

Journal Articles

A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell Lymphoma

David A. Bond, MD, Vedat Yildiz, Lai Wei, PhD, Lapo Alinari, MD PhD, Basem M. William, MRCP,MD, Jonathan E. Brammer, MD, Beth A. Christian, MD, Kristie A. Blum, MD, Kami J. Maddocks, MD

Blood (2019) 134 (Supplement_1): 4091.

https://doi.org/10.1182/blood-2019-130539

Published: 2019

Journal Articles

Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies

Blood (2018) 132 (Supplement 1): 228.

https://doi.org/10.1182/blood-2018-99-110220

Published: 2018

Journal Articles

Preliminary Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Kami J. Maddocks, MD, Farrukh T. Awan, MD MS, Ying Huang, MA, MS, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Narendranath Epperla, MD MS, Samantha Jaglowski, MD MPH, Basem M. William, MRCP, MD, Kristie A. Blum, MD, Beth A. Christian, MD

Blood (2018) 132 (Supplement 1): 4185.

https://doi.org/10.1182/blood-2018-99-117172

Published: 2018

Journal Articles

Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing)

Ranjana H. Advani, MD, Alison J. Moskowitz, MD, Nancy L. Bartlett, MD, Julie M. Vose, MDMBA, Radhakrishnan Ramchandren, MD, Tatyana A. Feldman, MD, Ann S. LaCasce, MD MSc, Beth A. Christian, MD, Stephen M. Ansell, MD PhD, Craig H. Moskowitz, MD, Keenan Fenton, Carol Anne Ogden, PhD, David Taft, Daniel E. Zak, PhD, Mariana Sacchi, MD, Faith Galderisi, DO, Alex F. Herrera, MD

Blood (2018) 132 (Supplement 1): 1635.

https://doi.org/10.1182/blood-2018-99-110002

Published: 2018

Journal Articles

Major Bleeding Complications Among Patients Treated with Ibrutinib and Concomitant Antiplatelet, Anticoagulant, or Supplemental Therapy

Aaron Pavlik, PharmD, Hallie Barr, PharmD, BCOP, Emily Dotson, PharmD, BCOP, John C. Byrd, MD, Kristie A. Blum, MD, Farrukh T. Awan, Jennifer A. Woyach, MD, Kami J. Maddocks, MD, Beth A Christian, MD, Jeffrey Jones, MD MPH

Blood (2016) 128 (22): 4387.

https://doi.org/10.1182/blood.V128.22.4387.4387

Published: 2016

Journal Articles

a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)

Kami J. Maddocks, MD, Jonathon B. Cohen, MD, Ying Huang, MA, MS, Beth A Christian, MD, Don M Benson, MD PhD, Jeffrey Jones, MD MPH, Christopher Flowers, MD MS, Leonard T. Heffner, MD, Cynthia Jenkins, RN, Jennfer Sexton, MHA, CCRC, Alison Neal, MPH, Melissa Kives, MPH, Kristie A. Blum, MD

Blood (2016) 128 (22): 1776.

https://doi.org/10.1182/blood.V128.22.1776.1776

Published: 2016

Journal Articles

Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center

Tracy E Wiczer, PharmD, BCOP, Lauren B Levine, PharmD, BCOP, Jessica Brumbaugh, Jessica Coggins, Qiuhong Zhao, MS, Amy S. Ruppert, MAS, Anli McCoy, PharmD, Kami J. Maddocks, MD, Beth A Christian, MD, Kerry A. Rogers, MD, Leslie Andritsos, MD, Samantha Jaglowski, MD MPH, Steven M Devine, MD, Pierluigi Porcu, MD, Jennifer A. Woyach, MD, Jeffrey Jones, MD MPH, Michael R. Grever, MD, John C. Byrd, MD, Farrukh T. Awan

Blood (2016) 128 (22): 2040.

https://doi.org/10.1182/blood.V128.22.2040.2040

Published: 2016

Journal Articles

A Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma (NHL)

Kami J. Maddocks, MD, Jonathon B. Cohen, MD, Beth A Christian, MD, Don M Benson, MD PhD, Kristie A. Blum, MD

Blood (2015) 126 (23): 5114.

https://doi.org/10.1182/blood.V126.23.5114.5114

Published: 2015

Journal Articles

Updated Results of a Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma

Beth A Christian, MD, John G. Kuruvilla, MD, Sonali M. Smith, MD, Pierluigi Porcu, MD, Kami J. Maddocks, MD, Amy S. Ruppert, MAS, John C Byrd, MD, Michael R. Grever, MD, Kristie A. Blum, MD

Blood (2015) 126 (23): 3983.

https://doi.org/10.1182/blood.V126.23.3983.3983

Published: 2015

Journal Articles

Subcutaneous Injections of IMMU-114 (Anti-HLA-DR IgG4 Monoclonal Antibody): Initial Results of a Phase I First-in-Man Study in Hematologic Malignancies

Deborah M. Stephens, DO, Alexander N Starodub, MD PhD, John C Byrd, MD, Heather Horne, William A Wegener, MD PhD, David M Goldenberg, ScD, MD, Beth A Christian, MD

Blood (2015) 126 (23): 2740.

https://doi.org/10.1182/blood.V126.23.2740.2740

Published: 2015

Journal Articles

Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma

Lapo Alinari, Bo Yu, Beth A. Christian, Fengting Yan, Jungook Shin, Rosa Lapalombella, Erin Hertlein, Mark E. Lustberg, Carl Quinion, Xiaoli Zhang, Gerard Lozanski, Natarajan Muthusamy, Mette Prætorius-Ibba, Owen A. O'Connor, David M. Goldenberg, John C. Byrd, Kristie A. Blum, Robert A. Baiocchi

Blood (2011) 117 (17): 4530–4541.

https://doi.org/10.1182/blood-2010-08-303354

Published: 2011

Includes: Supplemental data

NARROW

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results

A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma

Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study

Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study

A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study

Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell Lymphoma

Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies

Preliminary Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing)

Major Bleeding Complications Among Patients Treated with Ibrutinib and Concomitant Antiplatelet, Anticoagulant, or Supplemental Therapy

a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)

Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center

A Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma (NHL)

Updated Results of a Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma

Subcutaneous Injections of IMMU-114 (Anti-HLA-DR IgG4 Monoclonal Antibody): Initial Results of a Phase I First-in-Man Study in Hematologic Malignancies

Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only